[HTML][HTML] Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB …
Journal of clinical oncology, 2010•ncbi.nlm.nih.gov
Purpose Bevacizumab is an antibody that binds vascular endothelial growth factor and has
activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-α) is the historic
standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab
plus IFN-α versus IFN-α monotherapy was conducted.
activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-α) is the historic
standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab
plus IFN-α versus IFN-α monotherapy was conducted.
Abstract
Purpose
Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-α) is the historic standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab plus IFN-α versus IFN-α monotherapy was conducted.
ncbi.nlm.nih.gov
